High-frequency chest wall oscillation therapy in amyotrophic lateral sclerosis

Carlayne E. Jackson, Dan H. Moore, Pamela Kittrell, Erik Ensrud

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the effectiveness of high-frequency chest wall oscillation (HFCWO) therapy in patients with amyotrophic lateral sclerosis (ALS). METHODS: A retrospective chart review was performed of 18 patients receiving HFCWO therapy. Data was obtained pre-treatment and post-treatment including ALS Functional Rating Scale-Revised (ALSFRS-R), forced vital capacity (FVC), maximal inspiratory pressure (MIP), peak cough expiratory flow (PCEF), and daytime oximetry. RESULTS: Daytime oximetry increased for 8 of 18 patients. None of the other measures changed significantly over the 3 months, although the change in slope of FVC, MIP, and PCEF following initiation of treatment suggested a reduction in the rate of decline of each measure. A patient survey revealed that 92% felt better after therapy and that their breathing was easier. Of patients, 85% agreed that it was easier to clear airways and that it had improved their quality of life. CONCLUSIONS: HFCWO appears to be an effective tool for airway secretion management in ALS patients and may also have an impact in improving daytime oxygen saturation.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalJournal of clinical neuromuscular disease
Volume8
Issue number2
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Chest Wall Oscillation
Amyotrophic Lateral Sclerosis
Oximetry
Vital Capacity
Cough
Therapeutics
Airway Management
Respiration
Quality of Life
Oxygen

Keywords

  • Amyotrophic lateral sclerosis
  • Cough augmentation
  • High- frequency chest wall oscillation
  • Respiratory management
  • Secretion management

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

High-frequency chest wall oscillation therapy in amyotrophic lateral sclerosis. / Jackson, Carlayne E.; Moore, Dan H.; Kittrell, Pamela; Ensrud, Erik.

In: Journal of clinical neuromuscular disease, Vol. 8, No. 2, 01.12.2006, p. 60-64.

Research output: Contribution to journalArticle

Jackson, Carlayne E. ; Moore, Dan H. ; Kittrell, Pamela ; Ensrud, Erik. / High-frequency chest wall oscillation therapy in amyotrophic lateral sclerosis. In: Journal of clinical neuromuscular disease. 2006 ; Vol. 8, No. 2. pp. 60-64.
@article{e2f4b03416284c178c8dc97c1d963316,
title = "High-frequency chest wall oscillation therapy in amyotrophic lateral sclerosis",
abstract = "OBJECTIVES: To evaluate the effectiveness of high-frequency chest wall oscillation (HFCWO) therapy in patients with amyotrophic lateral sclerosis (ALS). METHODS: A retrospective chart review was performed of 18 patients receiving HFCWO therapy. Data was obtained pre-treatment and post-treatment including ALS Functional Rating Scale-Revised (ALSFRS-R), forced vital capacity (FVC), maximal inspiratory pressure (MIP), peak cough expiratory flow (PCEF), and daytime oximetry. RESULTS: Daytime oximetry increased for 8 of 18 patients. None of the other measures changed significantly over the 3 months, although the change in slope of FVC, MIP, and PCEF following initiation of treatment suggested a reduction in the rate of decline of each measure. A patient survey revealed that 92{\%} felt better after therapy and that their breathing was easier. Of patients, 85{\%} agreed that it was easier to clear airways and that it had improved their quality of life. CONCLUSIONS: HFCWO appears to be an effective tool for airway secretion management in ALS patients and may also have an impact in improving daytime oxygen saturation.",
keywords = "Amyotrophic lateral sclerosis, Cough augmentation, High- frequency chest wall oscillation, Respiratory management, Secretion management",
author = "Jackson, {Carlayne E.} and Moore, {Dan H.} and Pamela Kittrell and Erik Ensrud",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/01.cnd.0000249872.29091.9a",
language = "English (US)",
volume = "8",
pages = "60--64",
journal = "Journal of Clinical Neuromuscular Disease",
issn = "1522-0443",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - High-frequency chest wall oscillation therapy in amyotrophic lateral sclerosis

AU - Jackson, Carlayne E.

AU - Moore, Dan H.

AU - Kittrell, Pamela

AU - Ensrud, Erik

PY - 2006/12/1

Y1 - 2006/12/1

N2 - OBJECTIVES: To evaluate the effectiveness of high-frequency chest wall oscillation (HFCWO) therapy in patients with amyotrophic lateral sclerosis (ALS). METHODS: A retrospective chart review was performed of 18 patients receiving HFCWO therapy. Data was obtained pre-treatment and post-treatment including ALS Functional Rating Scale-Revised (ALSFRS-R), forced vital capacity (FVC), maximal inspiratory pressure (MIP), peak cough expiratory flow (PCEF), and daytime oximetry. RESULTS: Daytime oximetry increased for 8 of 18 patients. None of the other measures changed significantly over the 3 months, although the change in slope of FVC, MIP, and PCEF following initiation of treatment suggested a reduction in the rate of decline of each measure. A patient survey revealed that 92% felt better after therapy and that their breathing was easier. Of patients, 85% agreed that it was easier to clear airways and that it had improved their quality of life. CONCLUSIONS: HFCWO appears to be an effective tool for airway secretion management in ALS patients and may also have an impact in improving daytime oxygen saturation.

AB - OBJECTIVES: To evaluate the effectiveness of high-frequency chest wall oscillation (HFCWO) therapy in patients with amyotrophic lateral sclerosis (ALS). METHODS: A retrospective chart review was performed of 18 patients receiving HFCWO therapy. Data was obtained pre-treatment and post-treatment including ALS Functional Rating Scale-Revised (ALSFRS-R), forced vital capacity (FVC), maximal inspiratory pressure (MIP), peak cough expiratory flow (PCEF), and daytime oximetry. RESULTS: Daytime oximetry increased for 8 of 18 patients. None of the other measures changed significantly over the 3 months, although the change in slope of FVC, MIP, and PCEF following initiation of treatment suggested a reduction in the rate of decline of each measure. A patient survey revealed that 92% felt better after therapy and that their breathing was easier. Of patients, 85% agreed that it was easier to clear airways and that it had improved their quality of life. CONCLUSIONS: HFCWO appears to be an effective tool for airway secretion management in ALS patients and may also have an impact in improving daytime oxygen saturation.

KW - Amyotrophic lateral sclerosis

KW - Cough augmentation

KW - High- frequency chest wall oscillation

KW - Respiratory management

KW - Secretion management

UR - http://www.scopus.com/inward/record.url?scp=33845595861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845595861&partnerID=8YFLogxK

U2 - 10.1097/01.cnd.0000249872.29091.9a

DO - 10.1097/01.cnd.0000249872.29091.9a

M3 - Article

VL - 8

SP - 60

EP - 64

JO - Journal of Clinical Neuromuscular Disease

JF - Journal of Clinical Neuromuscular Disease

SN - 1522-0443

IS - 2

ER -